Tumour-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signalling.

Niamh Leonard; Shania M. Corry; Eileen Reidy; Hannah Egan; Grace O’Malley; Kerry Thompson; Emma McDermott; Aoise O’Neill; Norashikin Zakaria; Laurence J. Egan; Thomas Ritter; Daniela Loessner; Keara L. Redmond; Mary C. Sheehan; Aoife Canney; Aisling Hogan; Seán O. Hynes; Oliver Treacy; Philip D. Dunne; Aideen E. Ryan

doi:10.1016/j.isci.2024.110701

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

CMS4 colorectal cancer (CRC), based on the consensus molecular subtype (CMS), stratifies patients with the poorest disease-free survival rates. It is characterized by a strong mesenchymal stromal cell (MSC) signature, wound healing-like inflammation and therapy resistance. We utilized 2D and 3D

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leonard et al. (2024) studied this question.

synapsesocial.com/papers/68e5b146b6db64358754affd https://doi.org/10.1016/j.isci.2024.110701

View Full Paper

Ask AI

Bookmark

Share

Tumour-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signalling.

Ask about this paper

Abstract

Discussion

Cite This Study

Tumour-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signalling.

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading